Safety Study of CAT-8015 Immunoxin in Patients With NHL With Advance Disease

NCT00515892 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Leukemia
Non-Hodgkin's Lymphoma
NHL

Interventions

DRUG: Immunotoxin therapy
DRUG: CAT-8015 Immunotoxin
PROCEDURE: Biological therapy
PROCEDURE: Antibody Therapy
PROCEDURE: Monoclonal Antibody Therapy

Sponsor

Cambridge Antibody Technology